A drug called doramectin slowed tumor cells from spreading in lab tests
Original title: Multi-omics integration and functional validation identify thrombospondin-1 as a functionally relevant mediator of doramectin-associated inhibition of glioblastoma migration and invasion.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only done in tumor cells in a dish, not in people.
The short version
In lab dishes, this drug made glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary cells move and spread much less.
What was studied. Researchers treated rat glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary cells with a drug called doramectin. They watched how the cells stuck, moved, and spread, and they checked which genes changed.
What they found. The drug changed 3747 genes in the cells. 1660 genes went up and 2087 went down. One gene, called THBS1, dropped sharply after treatment. At the highest dose tested, cell movement and spread fell by about 82-93% compared to cells with no drug.
What this means, and what it doesn't
What it could mean: This points to one possible way to slow tumor cells from spreading. It also names a gene, THBS1, that may help tumor cells invade. That gives scientists a target to study next.
What it doesn't mean: This does not mean there is a new treatment. All of this was done in cells in a dish, not in people. No one knows yet if the drug is safe or helpful for a person with a brain tumor. It is not a cure, and it is many years away from everyday care.
Source: PubMed, August 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.